Home . Immediapress . Chimica e Farmacia . Norgine and Its Partner Salix Present New Data From PLENVU® (NER1006) Phase 3 Studies at Digestive Disease Week (DDW) 2018

Norgine and Its Partner Salix Present New Data From PLENVU® (NER1006) Phase 3 Studies at Digestive Disease Week (DDW) 2018

CHIMICA E FARMACIA

AMSTERDAM, June 5, 2018 /PRNewswire/ --

Norgine B.V. today with its partner Salix Pharmaceuticals, Ltd. ("Salix"), announced that they will present new data from phase 3 clinical trials for PLENVU® at Digestive Disease Week (DDW) in Washington, D.C., from June 2-5, 2018.

     (Logo: http://mma.prnewswire.com/media/597589/Norgine_Logo.jpg )

PLENVU® is a low-volume (1L) polyethylene glycol based bowel preparation indicated for adults.

PLENVU® data presented at DDW on 5 June 2018 from 12:00 to 14:00 EST, include:

PLENVU® is approved in Europe and in the US. In Europe, PLENVU® is available through Norgine and in the US through its partner Salix Pharmaceuticals.

Norgine manufactures PLENVU® globally.

GL/PLV/0518/0071

Media Contact:Isabelle Jouin, T: +44(0)1895-826237 Follow us @norgine

RIPRODUZIONE RISERVATA © Copyright Adnkronos.